Dr. Vahdat on Frontline Eribulin Plus Trastuzumab in MBC

Video

Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.

Linda T. Vahdat, MD, the director of the Breast Cancer Research Program and head of the Solid Tumor Service at the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer (MBC).

A phase II trial, known as the 208 Study, was undertaken to examine the safety and efficacy of combining trastuzumab and eribulin in HER2-positive MBC. Combining therapies with trastuzumab has produced promising results, Vahdat notes. She adds that prior to the trial this seemed like a natural combination.

At a planned interim analysis, 40 patients were evaluated. At this point, the objective response rate for the combination was 55% and progression-free survival was 9.2 months. In general, the combination was safe and did not result in any unexpected side effects, Vahdat notes.

Related Videos
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Rohan Garje, MD
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Samer A. Srour, MB ChB, MS
Rita Nanda, MD